Table 5 Response to infliximab according to GenPhenReSa sarcoidosis cluster among the 54 patients eligible for efficacy assessment. Fisher’s exact test
Cluster | Response | Failure | ρ-value |
|---|---|---|---|
Group 1 “AO,” n = 9 Abdominal Organs (kidney-liver-spleen) | 7 (77%) | 2 (23%) | 0.7 |
Group 2 “OCCC,” n = 21 Ocular-Cardiac-Cutaneous-CNS | 19 (90%) | 2 (10%) | 0.01 |
Group 3 “MSC,” n = 10 Musculoskeletal-Cutaneous | 3 (30%) | 7 (70%) | 0.004 |
Group 4, “PLN,” n = 8 Pulmonary-Lympho-Nodal | 5 (62.5%) | 3 (37,5%) | 0.7 |
Group 5 “EP,” n = 6 Extra-Pulmonary | 4 (67%) | 2 (33%) | 1 |